Xebra Brands Ltd. (“Xebra”) (XBRA: CSE) (9YC: FSE), a cannabis company, is pleased to announce that it has commenced its pre-trial cultivation of cannabis in the Netherlands. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. All statements, other than statements of historical facts, are forward-looking information and statements. The foregoing list is not exhaustive and XEBRA undertakes no obligation to update or revise any of the foregoing except as required by law. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by XEBRA as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies.
Xebra Brands Ltd. (“Xebra”) (XBRA: CSE) (9YC: FSE), a cannabis company, is pleased to announce that it has commenced its pre-trial cultivation of cannabis in the Netherlands.
As 1 of only 5 companies to be selected by the Dutch government to participate in trial medicinal cannabis cultivation, Xebra is endeavoring to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to €70.5 million, to co-supply all pharma-grade cannabis to be sold in the Netherlands.
Cultivation in the Netherlands is conducted in Xebra’s indoor facility. Xebra’s specific genetic varieties are characterized by high production,...
Read the full article @ Cannabis Law Report